BD, the Franklin Lakes, New Jersey-based medical technology company, plans to invest $110 million to expand syringe manufacturing capabilities in Columbus, Nebraska, to support the growing demand for biologic and GLP-1 drug delivery.

The investment will bring production of the BD Neopak Glass Prefillable Syringe to the site and create approximately 120 new jobs.

The move is part of BD’s broader effort to bolster the domestic pharmaceutical supply chain. Of the total investment, $100 million will fund new Neopak syringe production lines and related upgrades at the Columbus facility, with production expected to begin in mid-2026. An additional $10 million will go toward enhancing cannula manufacturing operations already in place at the site.
“As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “This investment in Nebraska advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions.”

The BD Neopak syringe line is designed for biologics and high-viscosity drug formulations, and is compatible with a range of delivery devices, including autoinjectors. The product will be available in 1 mL and 2.25 mL formats.

The Columbus site has played a strategic role in BD’s manufacturing network for more than 75 years. In a separate investment announced earlier, the company allocated over $35 million to expand its prefilled flush syringe manufacturing in Columbus, adding about 50 jobs.

The combined initiatives are part of BD’s broader plan to invest more than $2.5 billion in U.S. manufacturing over the next five years.

Business Affairs Homepage